With a team led by Dr. Jörg Schewe, partner at the Hamburg office of commercial law firm Heuking Kühn Lüer Wojtek, BSN medical (BSN) acquired Sorbion GmbH & Co. KG (Sorbion). The client was compehensively advised in corporate, antitrust, tax, and employment law. The acquisition price was not disclosed. The transaction is subject to the approval by the Federal Cartel Office.
Sorbion is an owner-operated company headquartered in Senden (Münsterland), specializing in the development, production and sale of products for modern wound treatment. BSN, which is also operating in this sector, intends to further strengthen its market position wih the acquisition. It concentrates on the marketing of high-quality medical products in the areas of wound and vascular care (including, for example, Leukoplast®), as well as non-invasive orthopedics and is one of the global leaders in these fields. At present, the company employs about 5,500 in more than 30 countries. Since mid-2012, BSN has been part of private equity group EQT.
In the future, Sorbion will be included in BSN's "Wound Care & Vascular" division with revenues of some 500 million euros. With this transaction, BSN medical additionally supplements the recent market introduction of the Cura Sul® system developed for negative pressure wound therapy.
Counsel to BSN medical
Heuking Kühn Lüer Wojtek:
Dr. Jörg Schewe (M&A/Corporate, Lead),
Dr. Stefan Bretthauer (Antitrust),
Dr. Andreas Walle (Employment),
Fabian G. Gaffron (Tax),
Christoph Prochnau (Corporate/Commercial),
Eva Schreiber (Employment), all Hamburg